Table 2 Characteristics of immunocompromised and non- immunocompromised IPA patients
IPA patients (n = 254) | Immunocompromised (n = 66) | non- immunocompromised (n = 188) | p value | |
|---|---|---|---|---|
Demographics | ||||
Sex, male (%) | 179 (70.5%) | 42 (72.9%) | 137 (63.6%) | 0.157 |
Age, yrs. | 61 ± 15 | 54 ± 15 | 64 ± 15 | < 0.001* |
Admission data | ||||
Diagnostic time, days (IQR) | 20 (12 ~ 30) | 18 (10 ~ 36) | 20 (12 ~ 30) | 0.461 |
Mechanical ventilation | 51 (20.1%) | 18 (27.1%) | 33 (17.6%) | 0.09 |
ICU admission | 62 (24.4%) | 22 (33.3%) | 40 (21.3%) | 0.05 |
Poor prognosis | 57 (22.4%) | 23 (34.8%) | 34 (18.1%) | 0.005* |
Symptoms | ||||
fever | 188 (74.0%) | 44 (66.7%) | 144 (76.6%) | 0.114 |
productive cough | 226 (89.0%) | 53 (80.3%) | 173 (92.0%) | 0.009* |
hemoptysis | 38 (15.0%) | 8 (12.1%) | 30 (16.0%) | 0.452 |
dyspnea | 158 (62.2%) | 37 (56.1%) | 121 (64.4%) | 0.231 |
chest pain | 15 (5.9%) | 3 (4.5%) | 12 (6.4%) | 0.586 |
Diagnostics | ||||
Histopathology | 46 | 10 | 36 | |
Lung tissue culture of positive | 29 | 1 | 28 | |
Culture of LRT preformed | 254 | 66 | 188 | |
LRT culture positive | 196 (77.1%) | 50 (75.7%) | 146 (77.7%) | 0.553 |
Serum GM preformed | 107 | 19 | 88 | |
Serum GM positive | 59 (55.1%) | 12 (63.1%) | 47 (53.4%) | 0.388 |
BALF GM preformed | 38 | 7 | 31 | |
BALF GM positive | 36 (94.7%) | 7 (100%) | 29 (93.4%) | 0.490 |